IL6 and graft versus host disease: Given the central role of IL-6 in the pathophysiology of CRS, tocilizumab, a monoclonal antibody against IL-6 receptor, has become standard of care for management of CRS in multiple settings and is being explored for prevention of GVHD as well (60, 64, 70).